Part One of Coventry’s 2017 Drug Trends Series reported the largest drop in Morphine Equivalent Dose (MED) in the last three years. As an indicator of increased chances for adverse outcomes, including death from overdose, these and other inroads are essential in the effort to curtail opioid misuse. To learn more about MED and its impact watch our latest video blog.
On October 18, 2021, Seglentis was approved by the U.S. Food and Drug Administration (FDA).
When adjusters have to jump through hoops to make referrals, they lose precious time.
On July 2, 2021, Michigan’s new auto fee schedule went into effect for services rendered on or after that date.
SAN DIEGO—October 19, 2021—Enlyte, the new parent brand unifying Mitchell, Genex and Coventry, today released its inaugural report
SAN DIEGO, CA—October 13, 2021—Mitchell, Genex and Coventry formally announced today the creation of their new parent brand, Enlyt
As a unified brand, Enlyte aligns the companies’ teams to enable improved client focus, while leveraging the breadth of solutions and expertis
